Zora biosciences licenses ceramide technology to quest diagnostics for cardiovascular mortality prediction test

Secaucus, n.j. and helsinki, march 15, 2021 /prnewswire/ -- zora biosciences oy, a clinical diagnostics company whose mission is to identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods, today announced it has signed a non-exclusive license agreement with quest diagnostics (nyse: dgx), the world leader in diagnostic information services, for zora's patented ceramide-analysis technology.
DGX Ratings Summary
DGX Quant Ranking